Ineffective treatment of PML with pembrolizumab
Open Access
- 1 November 2019
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
- Vol. 6 (6), e627
- https://doi.org/10.1212/nxi.0000000000000627
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Natalizumab-associated progressive multifocal leukoencephalopathy in GermanyNeurology, 2019
- Treatment of Progressive Multifocal Leukoencephalopathy with PembrolizumabThe New England Journal of Medicine, 2019
- Pembrolizumab Treatment for Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2019
- Can Immune Checkpoint Inhibitors Keep JC Virus in Check?The New England Journal of Medicine, 2019
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockadeNature Immunology, 2019
- TCR Bias and HLA Cross-Restriction Are Strategies of Human Brain-Infiltrating JC Virus-Specific CD4+ T Cells during Viral InfectionThe Journal of Immunology, 2012
- Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathyAIDS, 2003